Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.50 +0.11 (+0.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Via Stocktwits

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

January 11, 2026

From Beam Therapeutics

Via GlobeNewswire

Is Beam Therapeutics Gaining or Losing Market Support? ↗

September 22, 2025

Via Benzinga

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics (BEAM) Earnings Transcript ↗

November 27, 2025

Beam Therapeutics (BEAM) Earnings Transcript

Via The Motley Fool

Topics Death

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 12, 2025

From Beam Therapeutics

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...

Via Benzinga

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 04, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Beam Therapeutics

Via GlobeNewswire

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This...

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analysts also support Beam Therapeutics (BEAM) and Shopify (SHOP).

Via Benzinga

Topics Artificial Intelligence

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

Topics Artificial Intelligence Climate Change Economy

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Via Benzinga

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

August 05, 2025

From Beam Therapeutics

Via GlobeNewswire

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗

June 27, 2025

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.